ANGO News Alert Angiodynamics (ANGO) 19.19 12/25/2014 01:27:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Angiodynamics (ANGO) 19.19 $ANGO

Uptrend Call Working As Angiodynamics Stock Rises 25.0% (ANGO)
Comtex SmarTrend(R) - Mon Dec 22, 9:44AM CST
SmarTrend identified an Uptrend for Angiodynamics (NASDAQ:ANGO) on October 13th, 2014 at $15.24. In approximately 2 months, Angiodynamics has returned 24.98% as of today's recent price of $19.04.
ANGO: 19.19 (+0.33)

Merit Medical Hits 52-Week High on Product Pipeline Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 2:20PM CST
Strong third-quarter results, a string of FDA approvals for its new products along with a robust product pipeline, all contribute to the growth trajectory of Merit Medical Systems, Inc. (MMSI).
BSX: 13.13 (+0.07), TFX: 116.82 (+0.28), ANGO: 19.19 (+0.33), MMSI: 17.17 (+0.01)

AngioDynamics (ANGO) Hits 52-Week High on Positive View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 2:37PM CST
Shares of AngioDynamics Inc (ANGO) reached a 52-week high of $19.20 on Dec 17, 2014.
BSX: 13.13 (+0.07), BCR: 169.10 (-0.44), ANGO: 19.19 (+0.33), MMSI: 17.17 (+0.01)

CR Bard Strong on Acquisitions, FDA Nod for Lutonix DCB - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 3:55PM CST
CR Bard's initiative to introduce its products in the emerging markets is delivering accretive returns, as the company continues with its sturdy performance in the international markets.
BSX: 13.13 (+0.07), JNJ: 104.59 (+0.31), BCR: 169.10 (-0.44), ANGO: 19.19 (+0.33)

AngioDynamics reports January 8
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 7:37AM CST

ANGO: 19.19 (+0.33)

AngioDynamics to Report Fiscal 2015 Second Quarter Financial Results
GlobeNewswire - Wed Dec 17, 5:30AM CST
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2015 second quarter ended November 30, 2014, on Thursday, January 8, 2015, after the close of the U.S. financial markets.
ANGO: 19.19 (+0.33)

Merit Medical Wins FDA Approval for Multiple Devices - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 5:53PM CST
Developer of medical devices, Merit Medical Systems, Inc. (MMSI), recently announced that the U.S. Food and Drug Administration (FDA) has approved three of its products under section 510(k)
TFX: 116.82 (+0.28), ANGO: 19.19 (+0.33), MMSI: 17.17 (+0.01)

Shares of ANGO Up 24.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Dec 15, 9:17AM CST
SmarTrend identified an Uptrend for Angiodynamics (NASDAQ:ANGO) on October 13th, 2014 at $15.24. In approximately 2 months, Angiodynamics has returned 24.12% as of today's recent price of $18.91.
ANGO: 19.19 (+0.33)

AngioDynamics (ANGO) Signs PICC Deal with HealthTrust - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 3:50PM CST
AngioDynamics Inc. (ANGO) has entered into a strategic partnership with HealthTrust, covering AngioDynamics' PICC (peripherally inserted central catheter) products.
BCR: 169.10 (-0.44), VASC: 27.30 (+0.71), ANGO: 19.19 (+0.33), MMSI: 17.17 (+0.01)

AngioDynamics (ANGO) Highlighted As Strong And Under The Radar Stock Of The Day
at The Street - Thu Dec 11, 8:47AM CST
Trade-Ideas LLC identified AngioDynamics (ANGO) as a strong and under the radar candidate
ANGO: 19.19 (+0.33)

AngioDynamics Awarded HealthTrust PICC Contract
GlobeNewswire - Tue Dec 09, 5:33AM CST
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it signed an agreement with HealthTrust covering PICC (peripherally inserted central catheter) products.
ANGO: 19.19 (+0.33)

Angiodynamics Shares Up 14.5% Since SmarTrend's Buy Recommendation (ANGO)
Comtex SmarTrend(R) - Fri Dec 05, 5:11PM CST
SmarTrend identified an Uptrend for Angiodynamics (NASDAQ:ANGO) on October 13th, 2014 at $15.24. In approximately 2 months, Angiodynamics has returned 14.54% as of today's recent price of $17.45.
ANGO: 19.19 (+0.33)

Hologic (HOLX) Turns Around: Should You Invest Now? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 1:40PM CST
Hologic's (HOLX) international business, which had been underperforming over the past few quarters, showed a turnaround in the fourth quarter.
ETRM: 1.40 (-0.01), FLDM: 32.31 (+0.30), ANGO: 19.19 (+0.33), HOLX: 26.89 (+0.10)

SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into AngioDynamics Inc. Regarding Possible Breaches of Fiduciary Duty
Business Wire - Fri Dec 05, 12:57PM CST
Levi & Korsinsky, LLP is investigating AngioDynamics Inc. (NasdaqGS:ANGO) in connection with possible claims of breaches of fiduciary duty by certain members of the board of directors of the Company.
ANGO: 19.19 (+0.33)

Thoratec Completes Enrollment for HeartMate III CE Mark Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 5:10PM CST
Thoratec Corp (THOR) recently completed enrolment of 50 patients under the HeartMate III CE Mark trial at ten sites across Europe, Canada, and Australia.
FLDM: 32.31 (+0.30), EW: 130.75 (+1.17), THOR: 32.81 (+0.74), ANGO: 19.19 (+0.33)

Varian Medical (VAR) to Display New Technologies at RSNA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 12:50PM CST
Varian Medical Systems (VAR) will showcase new technologies in the ongoing (Nov 30 through Dec 5) annual meet of the Radiological Society of North America (RSNA).
VAR: 88.44 (+0.69), EW: 130.75 (+1.17), ARAY: 7.54 (+0.19), ANGO: 19.19 (+0.33)

Cepheid Wins FDA Clearance for Xpert Norovirus Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 1:40PM CST
Cepheid's (CPHD) Xpert Norovirus test comes as the much-desired solution, with its capacity to determine the presence of Norovirus and accurately isolate the different groups of this pathogen
ETRM: 1.40 (-0.01), FLDM: 32.31 (+0.30), CPHD: 53.39 (+0.51), ANGO: 19.19 (+0.33)

Luminex Grows on Product Launches & Strategic Partnerships - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 01, 2:00PM CST
We believe that Austin, TX-based Luminex Corporation (LMNX) has an interesting product pipeline and will significantly benefit from new products like ARIES and NxTAG.
FLDM: 32.31 (+0.30), EW: 130.75 (+1.17), LMNX: 18.60 (+0.37), ANGO: 19.19 (+0.33)

14.9% Return Seen to Date on SmarTrend Angiodynamics Call (ANGO)
Comtex SmarTrend(R) - Fri Nov 28, 4:56PM CST
SmarTrend identified an Uptrend for Angiodynamics (NASDAQ:ANGO) on October 13th, 2014 at $15.24. In approximately 2 months, Angiodynamics has returned 14.87% as of today's recent price of $17.50.
ANGO: 19.19 (+0.33)

Edwards Lifesciences Strong on Robust Q3, Raised Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 28, 2:50PM CST
Edwards Lifesciences (EW) reported better-than-expected third-quarter 2014 financial results on Oct 23.
ETRM: 1.40 (-0.01), FLDM: 32.31 (+0.30), EW: 130.75 (+1.17), ANGO: 19.19 (+0.33)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Human Frontier Mission Puts AI Research on Display

Updated Category News Views 45

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 182

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 121

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 52

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 105

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 104

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 140

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 98

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 97

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading

Top 5 Most Recently Viewed Articles

Stellantis NV: Short Interest Shift Sparks Investor Sentiment Questions

Updated Category News Views 299

Stellantis NV's (NYSE:STLA) short interest saw a notable drop of 13.81% since its last report, now standing at 44.96 million shares sold short, or about 1.56% of all tradable shares. Sounds like good news, right? But hang on—this isn't just a free pass to pop the champagne. When we talk short interest, we're peeling back layers on market sentiment that can turn on a...

Continue Reading
Minerals Technologies Showcases Innovative PFAS Solutions at Symposium

Updated Category News Views 185

Minerals Technologies to Present at Gabelli Funds PFAS Symposium Minerals Technologies Inc. (MTI) is thrilled to announce its participation in the upcoming PFAS Symposium hosted by Gabelli Funds. This notable event is set to take place in New York City, bringing together key figures in the industry to discuss significant advancements and novel strategies for tackling...

Continue Reading
Morning Market Insights for Key Stocks: A Daily Review

Updated Category News Views 338

Daily Market Insights: Leading Stocks to Watch Good morning, traders. Today’s notes zero in on SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA—names that tend to steer the broader tape. Our read on price comes from a blend of key levels shaped by price action, trading volume, and options flow. We refresh these levels daily and share them with Market Clubhouse...

Continue Reading
Exploring the Evolving Landscape of Electric Vehicles in the U.S.

Updated Category News Views 224

The Current State of Electric Vehicles in the U.S. The electric vehicle (EV) landscape in the U.S. is experiencing transformative changes. As the country marks significant milestones in EV deployment, there are noteworthy gaps in infrastructure and consumer attitudes that need addressing. The third annual HERE-SBD EV Index reveals how far the U.S. has come, yet highlights...

Continue Reading
eBay's Legal Victory: Dismissal of Harmful Product Claims

Updated Category News Views 173

eBay's legal drama hit the news when the U.S. government slammed them with a lawsuit accusing the online giant of violating the Clean Air Act back in 2024. The crux? Selling products that supposedly helped folks skirt around those pesky auto pollution controls. You know how it is—desks buzzing about regulatory risks, and traders getting twitchy over such moves. The...

Continue Reading